This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

ECASS I, ECASS II and ATLANTIS trials

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The results of the European Cooperative Acute Stroke Study I (ECASS I), ECASS II and the ATLANTIS trial (Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischaemic Stroke) showed that t-PA was not more effective than placebo in improving neurological outcome at 3 months.

The ECASS I trial employed a regime of 1.1 mg tPA per kg, a higher dose than in the NINDS rt-PA study and this seems to have led to a higher incidence of intracerebral haematoma 19.8 %. The ECASS II and ATLANTIS trials used a lower dose of 0.9 mg/kg with a combined incidence of 8% compared to 2.4% in the placebo group.

A post-hoc analysis of ECASS II has revealed a lower rate of death and dependency among thos patients treated with t-PA compared with those treated with placebo.

Critics of these trials suggest that compared to the NINDS trial therapy was given much later.

Reference:

  • (1) Brott, Bogousslavsky (2000). Treatment of acute ischaemic stroke. NEJM, 343, 710-722

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.